Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/715446/000149315222016452/form10-q.htm
April 2022
March 2022
December 2021
October 2021
October 2021
June 2021
May 2021
April 2021
March 2021
January 2021
Cover - shares | 6 Months Ended | |
---|---|---|
Apr. 30, 2022 | Jun. 10, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Apr. 30, 2022 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2022 | |
Current Fiscal Year End Date | --10-31 | |
Entity File Number | 001-37492 | |
Entity Registrant Name | ANIXABIOSCIENCES, INC. | |
Entity Central Index Key | 0000715446 | |
Entity Tax Identification Number | 11-2622630 | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, Address Line One | 3150 Almaden Expressway | |
Entity Address, Address Line Two | Suite 250 | |
Entity Address, City or Town | San Jose | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 95118 | |
City Area Code | (408) | |
Local Phone Number | 708-9808 | |
Title of 12(b) Security | Common Stock, par value $.01 per share | |
Trading Symbol | ANIX | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 30,471,001 |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/715446/000149315222016452/form10-q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Anixa Biosciences Inc.
Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Rating
Learn More![]()
The increase in research and development expenses was primarily due to an increase in employee stock option compensation expense of approximately $1,446,000, an increase in employee compensation and related costs, other than stock option compensation expense, of approximately $340,000, an increase in outside research and development expense related to our anti-viral drug program of approximately $96,000, an increase in outside research and development expense related to ovarian cancer program of approximately $71,000, an increase of approximately $59,000 of consultant stock option and warrant expense, offset by a decrease of approximately $180,000 in outside research and development related to our CAR-T therapeutics program and a decrease in license fees of approximately $110,000.
Accordingly, the performance obligations from this license agreement were satisfied and 100% of the revenue was recognized upon execution of the license agreement.
Accordingly, the performance obligations from these agreements were satisfied and 100% of the revenue was recognized upon the execution of the agreements.
The increase in research and development expenses was primarily due to an increase in employee stock option compensation expense of approximately $529,000, an increase in employee compensation and related costs, other than stock option compensation expense, of approximately $254,000, an increase in outside research and development expense related to our anti-viral drug program of approximately $81,000, offset by a decrease of approximately $158,000 in outside research and development related to our CAR-T therapeutics program.
The net loss attributable to noncontrolling interest, representing Wistar's 5% ownership interest in Certainty's net loss, was approximately $44,000 and $38,000, respectively, in the three months ended April 30, 2022 and 2021.
The net loss attributable to...Read more
We can give no assurance...Read more
General and Administrative Expenses General...Read more
General and Administrative Expenses General...Read more
The increase in general and...Read more
We do not believe that...Read more
As a result, our cash,...Read more
22 We believe that, of...Read more
The increase in general and...Read more
Our revenue arrangements provide for...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits
Ticker: ANIX
CIK: 715446
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-22-016452
Submitted to the SEC: Fri Jun 10 2022 4:22:36 PM EST
Accepted by the SEC: Fri Jun 10 2022
Period: Saturday, April 30, 2022
Industry: Medical Laboratories